Introduction
============

Pancreatic cancer is a highly aggressive cancer, with a 5-year overall survival (OS) rate of \<1.0%, and is one of the most frequent causes of cancer-associated mortality worldwide ([@b1-ol-0-0-7218]). The poor outcome for patients with pancreatic cancer is associated with its late diagnosis due to the paucity of symptoms, rapid tumor progression and unresponsiveness to chemotherapy or radiotherapy. These parameters result in low resectability rates following diagnosis, early recurrence subsequent to resection and an overall poor survival rate ([@b2-ol-0-0-7218]). Therefore, pancreatic cancer is the object of extensive study, to obtain an improved understanding of the development and progression of the disease, and to improve the survival and quality of life of patients.

In total, \>90% of pancreatic cancer cases arise from the ductal epithelium of the pancreas and are termed pancreatic ductal adenocarcinoma (PDAC). Extensive efforts have been made to identify potential biomarkers that may be used to develop anti-metastatic treatments and improve prognostic evaluation ([@b3-ol-0-0-7218]). Unlike PDACs, solid pseudopapillary neoplasms (SPNs) of the pancreas are distinctive tumors that exhibit a low malignancy potential and are associated with a favorable prognosis following resection ([@b4-ol-0-0-7218]).

Autophagy, which is known as type II programmed cell death, is an important pathway for the degradation and recycling of cellular components and the response to stress ([@b5-ol-0-0-7218]). At basal levels, autophagy controls cellular homeostasis by removing potential intrinsic toxic components and enables cells to perform structural remodeling, which serves an essential role in cellular differentiation, development and survival in response to starvation conditions ([@b6-ol-0-0-7218],[@b7-ol-0-0-7218]). The aberrant regulation of these mechanisms contributes to the pathogenesis of a variety of diseases, including cancer ([@b6-ol-0-0-7218],[@b8-ol-0-0-7218]).

The Beclin 1 gene was the first mammalian autophagy gene identified, and it is located on chromosome 17q21 ([@b6-ol-0-0-7218]). Beclin 1 has received special attention in studies investigating autophagy, as it is the first autophagy protein demonstrated to be a haploinsufficient tumor suppressor in cancer cell experiments ([@b9-ol-0-0-7218],[@b10-ol-0-0-7218]). However, studies associating Beclin 1 with the pathogenesis of human cancer are limited, and the correlation is controversial. Decreased expression of Beclin 1 has been detected in glioblastoma ([@b11-ol-0-0-7218]), hepatocellular carcinoma ([@b12-ol-0-0-7218]), esophageal cancer ([@b13-ol-0-0-7218]), non-small cell lung cancer ([@b14-ol-0-0-7218]), bladder urothelial tumors ([@b15-ol-0-0-7218]) and breast cancer ([@b16-ol-0-0-7218]), whilst increased expression of Beclin 1 has been identified in ovarian cancer ([@b17-ol-0-0-7218]), colorectal cancer ([@b18-ol-0-0-7218]) and gastric cancer ([@b19-ol-0-0-7218]).

The BCL2, apoptosis regulator (*BCL2*) gene, located on chromosome 18q21, is a member of the Bcl-2 family, which serves an important role in apoptosis suppression ([@b20-ol-0-0-7218],[@b21-ol-0-0-7218]). The anti-apoptotic function extends cell survival in normal and tumor cells by inhibiting different cell death mechanisms ([@b22-ol-0-0-7218]). Bcl-2 is involved in cellular morphogenesis and differentiation; it functions as an oncogenic and anti-death molecule by modulating various homeostatic, developmental and disease processes ([@b23-ol-0-0-7218]--[@b25-ol-0-0-7218]). Although overexpression of Bcl-2 confers a survival advantage to the cell that may lead to rapid and uncontrolled cellular proliferation, which characterizes the development of cancer, differences in the expression of Bcl-2 in numerous types of human cancer have been identified, similar to that found for Beclin 1. Bcl-2 downregulation has been revealed in breast cancer and pancreatic cancer ([@b26-ol-0-0-7218],[@b27-ol-0-0-7218]), whereas increased expression of Bcl-2 upregulation has also been demonstrated ([@b16-ol-0-0-7218],[@b28-ol-0-0-7218]). The significance of Bcl-2 expression for cancer prognosis remains unclear.

Beclin 1 was originally identified in a yeast two hybrid screen as a Bcl-2 family-interacting protein that serves a pivotal role in the process of autophagy ([@b29-ol-0-0-7218]). The binding between Beclin 1 and Bcl-2 is regulated by a variety of proteins and compounds that enhance or inhibit the Bcl-2/Beclin 1 interaction to repress or activate autophagy, and serve important roles in the crosstalk between autophagy and apoptosis ([@b30-ol-0-0-7218],[@b31-ol-0-0-7218]). The cooperation between Beclin 1 and Bcl-2 may additionally affect tumorigenesis and progression.

Studies suggest that Beclin1 and Bcl-2 expression in tumor cells varies according to tumor and tissue type, which requires additional investigation ([@b11-ol-0-0-7218]--[@b19-ol-0-0-7218],[@b26-ol-0-0-7218]--[@b28-ol-0-0-7218]). There is a study that assesses Beclin 1 and Bcl-2 expression levels in pancreatic tumors, their interactions, and the correlation between their expression and patient survival ([@b32-ol-0-0-7218]). The aim of the present study was to examine the expression of Beclin 1 and Bcl-2 by immunohistochemistry in pancreatic neoplasms, including PDACs, SPNs and chronic pancreatitis (CP) tissues as the controls for PDAC. The expression of Beclin 1 and Bcl-2 was evaluated in correlation with clinicopathological parameters and the survival of patients to assess their value as markers of tumor development and prognosis.

Patients and methods
====================

### Patients and tissue samples

Formalin-fixed and paraffin-embedded tissue samples from 117 patients with PDAC, 43 patients with SPN and 32 patients with CP were selected from the archived materials of the Department of Pathology of Shengjing Hospital of China Medical University (Shenyang, China). The PDAC group consisted of 70 men and 47 women, the age of which ranged between 37 and 77 years (mean age ± standard deviation, 58.89±9.27). The SPN group consisted of 5 men and 38 women, the age of which ranged between 9 and 65 years (mean age ± standard deviation, 32.77±13.72). Patients diagnosed with PDAC, SPN or CP underwent pancreaticoduodenectomy or distal pancreatectomy between January 2011 and May 2014. Sufficient clinical and survival information of the PDAC and SPN patients was available.

Patients without complete survival information or those who succumbed to surgical complications were excluded from the study. No patients had received any neoadjuvant chemotherapy or chemoradiotherapy prior to the surgical resection. All patients were followed up by interview in the clinic or by phone call. Data on chemotherapy following surgery, disease-free survival (DFS) time and OS time were collected for each patient. Cases with distant metastasis or R1 resection were excluded from DFS evaluation. The total period of follow-up was 18--57 months.

All samples were initially stained with Mayer\'s hematoxylin for 5 min and 2% eosin for 1 min at room temperature; two independent investigators evaluated each section to confirm the foci and the differentiation of PDAC microscopically, and the most representative section from each case was used for immunohistochemical staining.

The present study was approved by the Clinical Ethics Committee of Shengjing Hospital of China Medical University.

### Immunohistochemistry

Immunohistochemical staining was performed using the biotin-free polymer detection system. The formalin-fixed, paraffin-embedded sections (4-µm thick) were deparaffinized and dehydrated via dimethylbenzene and a graded alcohol series, respectively.

Microwave antigen retrieval was achieved in sodium citrate buffer (pH 6.0) for Beclin 1, and in Tris-EDTA buffer (pH 9.0) for Bcl-2, each for 20 min at 100°C. Endogenous peroxidase activity was blocked by incubation with 0.3% hydrogen peroxidase at 37°C for 15 min. Sections were then incubated with primary mouse monoclonal antibodies against Beclin 1 (1:400; cat. no. ab114071; Abcam, Cambridge, UK) and rabbit monoclonal antibodies against Bcl-2 (1:350; cat. no. ab32124; Abcam) at 4°C overnight. A two-step immunohistochemical staining kit was used for expression analysis (cat. no. PV-9000; Zhongshan Jinqiao Biotechnology Co. Ltd., Beijing, China). Tissue sections were then incubated with a polymer auxiliary for 15 min at 37°C and a biotin-free polymeric horseradish peroxidase-linked antibody-conjugate agent from the kit for 25 min at 37°C. Following incubation, the reaction product was detected using diaminobenzidine (ZLI-9018; Zhongshan Jinqiao Biotechnology Co. Ltd., Beijing, China). Finally, the sections were counterstained with Mayer\'s hematoxylin as aforementioned, dehydrated, and mounted.

The normal ductal epithelium in breast tissue obtained from Pathology Department of Shengjing Hospital of China Medical University and the lymphocytes in the pancreatic stroma of the included pancreatic samples were used as positive controls for Beclin 1 and Bcl-2, respectively. The negative controls were obtained by replacing the primary antibodies with 0.01 mol/l phosphate-buffered saline.

Images were captured with a light microscope and NIS-Elements F3.0 software (Nikon Corporation, Tokyo, Japan).

### Evaluation of immunohistochemical staining

Immunohistochemical sections were independently evaluated by two investigators in a blinded manner. At least five fields at a magnification, ×400 were randomly chosen per section. Cytoplasmic or membranous staining for Beclin 1 and Bcl-2 was considered to represent a positive immunoreaction. Beclin 1 and Bcl-2 expression levels were estimated semiquantitatively based on the combination of staining intensity and the percentage of positively stained cells (proportion score). The staining intensity was scored as follows: 0, negative; 1, weak; 2, moderate; and 3, strong. According to the percentage of positively stained cells in whole foci, the staining extent was categorized into 5 grades as follows: 0, negative; 1, 0--25%; 2, 26--50%; 3, 51--75%; and 4, 76--100%. The intensity score and proportion score were multiplied together for a final score. Final scores were as follows for Beclin 1 and Bcl-2: \<6, low expression; and ≥6, high expression.

### Clinical outcome assessment

DFS was calculated from the date of surgery to the date of detection of local recurrence/distant metastasis or to the date of mortality due to PDAC. DFS was only calculated in patients with R0 resection (free resection margins). Patients with R1 resection (resection margins invaded) were considered to have failure at time zero. OS was defined as the time from the date of surgery to the date of mortality or to the date of last follow-up if patients remained alive. The DFS of patients with PDAC was acquired in 97 cases with R0 resection; the mean DFS was 10.9 months (median, 6.0 months; range, 0.8--32.7 months). The OS of patients with PDAC was acquired in 117 cases; the mean OS was 13.6 months (median, 10.4 months; range, 1.37--42.0 months). None of the patients with SPN exhibited local recurrence/distant metastasis or had succumbed by the date of last follow-up.

### Statistical analysis

Statistical analysis was performed using SPSS v.18.0 software (SPSS, Inc., Chicago, IL, USA). Pearson\'s χ^2^ test and Fisher\'s exact test were used to evaluate the association between Beclin 1 and Bcl-2 expression and several clinicopathological variables, and the difference between the Beclin 1 and Bcl-2 expression in PDAC and CP cases. The correlation coefficients (r and P-values) between Beclin 1 and Bcl-2 among PDAC, SPN and CP tissues were obtained using the Spearman\'s test. Survival curves of DFS and OS were analyzed by the Kaplan-Meier method and compared with the log-rank test. Multivariate analysis of prognostic factors was tested with the Cox proportional hazards model. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Beclin 1 expression in pancreatic neoplasms

Assessment of Beclin 1 expression in pancreatic tissues demonstrated positive staining in cancerous foci, SPN foci and normal epithelium in CP tissues, and in the cytoplasm of intralobular ductal epithelial cells, acinar cells and pancreatic islet cells ([Fig. 1](#f1-ol-0-0-7218){ref-type="fig"}). Pancreatic islet cells stained positive for Beclin 1, and were used as the positive control for Beclin 1 immunostaining in subsequent experiments. High Beclin 1 expression was observed in 74 (63.2%) PDAC cases, while 43 (36.8%) PDAC cases demonstrated low expression. PDAC tissues exhibited significantly higher Beclin 1 expression compared with the normal ductal epithelium in CP tissues (P=0.047) ([Table I](#tI-ol-0-0-7218){ref-type="table"}).

The association between Beclin 1 expression and the clinicopathological characteristics of patients with PDAC is described in [Table II](#tII-ol-0-0-7218){ref-type="table"}. High Beclin 1 expression was correlated with poor histological differentiation (P=0.001) and distant metastasis (P=0.021).

High Beclin 1 expression was detected in 26 (60.5%) patients with SPN and was correlated with pancreatic body or tail location (P=0.018) and the presence of nuclear pleomorphism (P=0.031). There was no significant correlation between Beclin 1 expression and other clinicopathological features ([Table III](#tIII-ol-0-0-7218){ref-type="table"}).

### Bcl-2 expression in pancreatic neoplasms

Cytoplasmic or membranous Bcl-2 immunostaining was observed in the majority of the normal ductal (intralobular and interlobular) cells and certain acinar compartments, whilst no staining was observed in the endocrine component ([Fig. 2](#f2-ol-0-0-7218){ref-type="fig"}).

Decreased Bcl-2 expression was detected in PDAC foci compared with the normal ductal epithelium ([Table I](#tI-ol-0-0-7218){ref-type="table"}). High Bcl-2 expression was detected in 38 (32.5%) PDAC cases, while 79 (67.5%) PDAC cases demonstrated low expression. The correlation between Bcl-2 and the clinicopathological characteristics of PDAC patients is summarized in [Table II](#tII-ol-0-0-7218){ref-type="table"}. Decreased Bcl-2 expression was correlated with cancerous pancreatic body or tail location (P=0.017), poor histological differentiation (P=0.002), distant metastasis (P=0.049) and advanced Tumor-Node-Metastasis (TNM) ([@b33-ol-0-0-7218]) stage (P=0.017).

High Bcl-2 expression was detected in 11 (25.6%) patients with SPN. There was no significant correlation between Bcl-2 expression and clinicopathological features in SPN ([Table III](#tIII-ol-0-0-7218){ref-type="table"}).

### Association between Beclin 1 and Bcl-2 expression

As demonstrated in [Table IV](#tIV-ol-0-0-7218){ref-type="table"}, Beclin 1 expression level was not associated with Bcl-2 expression in CP cases (P=0.629, r=0.073). However, there was a statistically significant inverse correlation (P\<0.001, r=−0.342) between the level of Beclin 1 and Bcl-2 expression in PDAC cases. A statistically significant direct correlation (P=0.016, r=0.365) was detected between Beclin 1 and Bcl-2 expression in SPN cases.

### Association of clinicopathological characteristics, Beclin 1/Bcl-2 expression and patient survival in PDAC: A univariate survival analysis

Univariate survival analysis with the Kaplan-Meier method and log-rank test was used to calculate the effect of well-established clinical prognostic factors and the levels of Beclin 1 and Bcl-2 expression on the DFS and OS of patients with PDAC ([Table V](#tV-ol-0-0-7218){ref-type="table"}). The outcomes demonstrated that longer DFS was significantly correlated with head location (P=0.001), improved differentiation (P\<0.001), limited tumor size and local invasion (T stage; P=0.003) and high expression of Bcl-2 (P=0.030). The median DFS of patients with high Beclin 1 expression was shorter compared with that of patients with low expression, although the difference did not reach statistical significance ([Fig. 3A](#f3-ol-0-0-7218){ref-type="fig"}).

The effects of prognostic factors on OS was next analyzed. The results demonstrated that a longer OS was significantly associated with pancreatic head location (P=0.004), improved differentiation (P\<0.001), limited tumor size and local invasion (P\<0.001), negative lymph node metastasis (P=0.022), no distant metastasis (P\<0.001) and lower TNM stage (P\<0.001). Low expression of Beclin 1 and high expression of Bcl-2 were predictive factors of improved OS (P=0.038 and P=0.017, respectively; [Fig. 3C and D](#f3-ol-0-0-7218){ref-type="fig"}).

### Independent prognostic factors of PDAC: A multivariate survival analysis

To avoid the bias of univariate analysis, the expression of Beclin 1, Bcl-2 and other characteristics were examined by multivariate Cox analysis ([Table V](#tV-ol-0-0-7218){ref-type="table"}). In the multivariate analysis, Beclin 1 and Bcl-2 were not independent prognostic parameters for DFS \[Beclin 1: Hazard ratio (HR), 0.870; 95% confidence interval (CI), 0.532--1.423; P=0.580; Bcl-2: HR, 1.400; 95% CI, 0.810--2.421; P=0.228\]. DFS was affected by improved differentiation (HR, 0.399; 95% CI, 0.190--0.839; P=0.015) and limited tumor size and local invasion (HR, 0.399; 95% CI, 0.190--0.839; P=0.014) independently.

Bcl-2 was an independent prognostic biomarker for OS (HR, 1.850; 95% CI, 1.053--3.249; P=0.032), whereas Beclin 1 was not an independent prognostic parameter for OS (HR, 0.927; 95% CI, 0.557--1.543; P=0.771). No smoking (HR, 0.546; 95% CI, 0.326--0.914; P=0.021), improved differentiation (HR, 0.394; 95% CI, 0.201--0.774; P=0.007), limited tumor size and local invasion (HR, 0.307; 95% CI, 0.175--0.539; P\<0.001) and chemotherapy following surgery (HR, 2.415; 95% CI, 1.218--4.544; P=0.006) were also associated with improved OS.

Discussion
==========

The burden of pancreatic cancer is increasing worldwide, making it a serious health concern. Risk factors such as older age, smoking and long-term diabetes mellitus have been associated with pancreatic tumorigenesis ([@b34-ol-0-0-7218]). Surgical resection is considered the best potentially curative treatment; however, the majority of patients are diagnosed at an unresectable locally advanced or distal metastatic stage due to the aggressiveness of the disease ([@b34-ol-0-0-7218]). The effects of surgical resection on OS remains minimal, and the local failure rate is as high as 50--80% in patients who successfully undergo surgical resection, resulting in poor quality of life ([@b35-ol-0-0-7218]). Pancreatic cancer is difficult to prevent and diagnose early; it progresses rapidly and exhibits a poor prognosis. Therefore, extensive studies have been conducted to understand the mechanisms underlying pancreatic cancer development at the biochemical, genomic and proteomic levels to inhibit the progression of pancreatic cancer and to improve patient prognosis.

Autophagy and apoptosis have been studied extensively in association with tumor progression in previous years, particularly Beclin 1 and Bcl-2 as the primary factors in the 2 programmed cell death pathways. The correlation between autophagy and apoptosis is complex and varies with cell type and stress stages ([@b31-ol-0-0-7218]). Autophagy may initiate or inhibit apoptosis depending on the cellular context and stimulus, and the inhibition of autophagy may increase the sensitivity of cells to apoptotic signals ([@b6-ol-0-0-7218]). The present study focused on analyzing the correlation between Beclin 1 and Bcl-2 expression in pancreatic tissues.

In previous studies, Beclin 1 downregulation was detected in glioblastoma, hepatocellular carcinoma, esophageal cancer, non-small cell lung cancer, bladder urothelial tumors and breast cancer ([@b11-ol-0-0-7218]--[@b16-ol-0-0-7218]), whereas Beclin 1 upregulation was identified in colorectal, ovarian and gastric cancer ([@b17-ol-0-0-7218]--[@b19-ol-0-0-7218]). The correlation between Beclin 1 expression and clinicopathological characteristics differs among different cancer tissues. Decreased expression of Beclin 1 is correlated with poor differentiation or advanced TNM stage, inducing early tumor relapse and causing low OS in glioblastoma ([@b11-ol-0-0-7218]), hepatocellular carcinoma ([@b12-ol-0-0-7218]), non-small cell lung cancer ([@b14-ol-0-0-7218]), breast cancer ([@b16-ol-0-0-7218]), ovarian cancer ([@b17-ol-0-0-7218]) and gastric carcinoma ([@b19-ol-0-0-7218]). Han *et al* ([@b18-ol-0-0-7218]) performed a meta-analysis, including six studies, to evaluate the prognostic significance of Beclin-1 expression in colorectal cancer, and revealed that Beclin 1 overexpression is associated with tumor metastasis and a poor prognosis in affected patients. Therefore, the effects of Beclin 1 expression levels differ among malignant tissues.

In the present study, high Beclin 1 expression was observed in 74 (63.2%) PDAC cases, while 43 (36,8%) PDAC cases exhibited low expression. Compared with the normal ductal epithelia in CP tissues, patients with PDAC demonstrated high Beclin 1 expression, and the difference was more apparent in poorly differentiated tissues and patients with advanced TNM stage. In the analysis of the correlations between Beclin 1 expression and clinicopathological characteristics, high Beclin 1 expression was associated with poor histological differentiation and distant metastasis. The univariate analysis of survival indicated that, despite a longer median DFS and OS in patients with low Beclin 1 expression compared with that in those patients with high expression, the difference was not statistically significant. In the multivariate Cox analysis, although low Beclin 1 expression was associated with improved OS (P\<0.05), it was not an independent prognostic factor for PDAC. The significant prognostic factors based on PDAC itself were the differentiation status, local advancement and distal metastasis. Taken together, these results suggest that Beclin 1 expression is upregulated in PDAC tissues, and increased Beclin 1 levels serve a significant role in PDAC progression. High Beclin 1 expression affects the survival of patients with PDAC by affecting tumor differentiation, local advancement and distal metastasis; however, it was not an independent indicator of prognosis in patients with PDAC in the present study.

To the best of our knowledge, there is only one previous study analyzing Beclin 1 expression in patients with PDAC. In that study, Kim *et al* ([@b36-ol-0-0-7218]) evaluated Beclin 1 expression levels in 63 PDAC cases, with positive expression in 14 (22.2%) cases and negative expression in 49 (77.8%) cases. The results of correlation and survival analyses were different from those of the present study, and the immunohistochemical pattern was also different. The opposite outcomes may be attributed to differences in the methods used. In the present study, the Power Vision two-step method was chosen to perform the immunohistochemical staining, whereas Kim *et al* ([@b36-ol-0-0-7218]) chose the streptavidin-peroxidase three-step method in their study. In our opinion, the streptavidin-peroxidase three-step method is not suited to pancreatic tissue.

Bcl-2 protein is considered a carcinogenic protein, as it contributes to apoptosis inhibition; its tumorigenic potential has been demonstrated in animal models ([@b37-ol-0-0-7218]) and is supported by its overexpression in a variety of tumors and in lymphomas, in which Bcl-2 acts as an oncogene ([@b38-ol-0-0-7218],[@b39-ol-0-0-7218]). However, in certain solid tumors, Bcl-2 paradoxically appears to exert a tumor suppressor effect, and its expression is associated with favorable prognostic features. Callagy *et al* ([@b40-ol-0-0-7218]) performed a meta-analysis, including 17 studies and 5,892 breast cancer cases, to determine whether Bcl-2 is an independent prognostic marker in breast cancer. The meta-analysis clearly supported the prognostic role of Bcl-2 expression in breast cancer, as assessed by immunohistochemistry, and demonstrated that it is associated with DFS and OS. The mechanisms by which Bcl-2 exerts its protective effects remain unclear.

In the present study, it was demonstrated that Bcl-2 expression was lower in PDAC tissues compared with the normal ductal epithelium in CP tissues, and that it was associated with poor differentiation, positive distant metastasis, advanced TNM stage and a poor prognosis. The outcomes revealed that Bcl-2 is downregulated in PDAC tissues and that Bcl-2 downregulation promotes PDAC progression, suggesting that Bcl-2 is an independent prognostic indicator in PDAC. Consistent with the results of the present study, previous studies demonstrated decreased Bcl-2 expression in PDAC cancerous foci, and low Bcl-2 expression was associated with poor differentiation and high TNM stage cases ([@b26-ol-0-0-7218],[@b41-ol-0-0-7218],[@b42-ol-0-0-7218]). However, the prognostic significance of Bcl-2 expression in patients with PDAC remains controversial, which may be attributed to population differences.

Knowlton *et al* ([@b43-ol-0-0-7218]) analyzed cell cycle progression in breast cancer cells and demonstrated a decreased S phase fraction and an increased G~1~/G~0~ fraction in Bcl-2(−) cells, suggesting that Bcl-2 prolongs the cell cycle. Additionally, Bcl-2 also enhanced the G~0~ fraction and delayed G~0~ to S transition ([@b44-ol-0-0-7218]). Ke *et al* ([@b45-ol-0-0-7218]) revealed that Bcl-2 upregulation serves a critical role in the regulation of cell adhesion and migration via the formation of Bcl-2 and gelsolin complexes, leading to the inhibition of cell diffusion, given the established correlation of cell motility with cancer metastasis. Despite the antiapoptotic effects favoring tumor survival, these results may explain why the expression of Bcl-2 in certain tumor cell types reduces the potential for metastasis and improves patient prognosis.

Another notable reason for the high relapse and low 5-year OS of PDAC is the poor sensitivity to chemotherapy, radiotherapy or immunotherapy. Therefore, a number of patients with PDAC refuse adjuvant therapy subsequent to surgery. As an important adjuvant therapy following tumor resection, chemotherapy serves an essential role in preventing tumor relapse and prolonging OS. Chemotherapy is the adjuvant therapy method considered to be potentially effective in PDAC ([@b2-ol-0-0-7218]). The modulation of cell apoptosis is one of the mechanisms of chemotherapy. A meta-analysis performed by Yang *et al* ([@b46-ol-0-0-7218]) revealed that Bcl-2 expression is a predictive factor for chemotherapy sensitivity, and negative Bcl-2 expression is associated with a good chemotherapy response in patients with breast cancer. Therefore, the modulation of Bcl-2 expression may potentially benefit additional clinical treatment for PDAC.

In the present study, Beclin 1 and Bcl-2 levels were inversely correlated in PDAC tissues. The inverse correlation between Beclin 1 and Bcl-2 expression has been demonstrated in previous studies ([@b16-ol-0-0-7218],[@b27-ol-0-0-7218],[@b28-ol-0-0-7218],[@b47-ol-0-0-7218]). Under normal conditions, Bcl-2 inhibits Beclin 1, whereas under conditions of stress, Beclin 1 dissociates from Bcl-2, allowing the activation of Vps34 and the subsequent stimulation of autophagy ([@b48-ol-0-0-7218]). Bcl-2 inhibits autophagy when bound to Beclin 1 and downregulates Beclin 1, which is associated with the outcomes of patients in the present study ([@b48-ol-0-0-7218]). Reduced Bcl-2 expression leads to decreased interaction with Beclin 1, resulting in increased Beclin 1 levels and the stimulation of autophagy, primarily in patients with PDAC with poor prognostic factors.

SPN was first described by Frantz in 1959 ([@b4-ol-0-0-7218]), and defined by the World Health Organization as a 'solid pseudopapillary neoplasm', a low grade malignant neoplasm of the exocrine pancreas in 2010 ([@b49-ol-0-0-7218]). SPNs primarily affect young women in their 20 sec and 30 sec, and generally form a well-demarcated mass with a mean diameter of 5--10 cm. Despite their large size, the majority of these tumors behave indolently; complete surgical resection of SPNs may lead to a favorable prognosis, with a 5-year survival rate \>95% ([@b50-ol-0-0-7218]).

The present study detected Beclin 1 and Bcl-2 expression in SPN tissues, and detected 26 (60.5%) cases with high Beclin 1 expression and 11 (25.6%) cases with high Bcl-2 expression. High Beclin 1 expression was significantly correlated with the presence of nuclear pleomorphism. This result confirmed that increased Beclin 1 expression leads to poor tumor differentiation. Unlike PDAC, a direct correlation was detected between the levels of Beclin 1 and Bcl-2 expression in SPN cases. Additionally, the expression levels of Beclin 1 and Bcl-2 in normal ductal epithelium of CP tissues were not correlated. The differences in expression patterns indicated the tissue specificity of Beclin 1 and Bcl-2, suggesting that autophagy and apoptosis exhibit separate regulatory mechanisms in SPN. None of the patients exhibited tumor relapse, and all patients were alive by the date of last follow-up.

The present study has several limitations. Firstly, normalized chemotherapy for PDAC is generally performed based on the guidelines for pancreatic cancer treatment; however, few patients undergo chemotherapy due to the poor sensitivity of PDAC to adjuvant therapy and the ineffectiveness of primary chemotherapy strategies for PDAC. Therefore, the present study was unable to collect a large sample size of PDAC cases to analyze the association between the sensitivity to chemotherapy and Beclin 1 and Bcl-2 expression. Secondly, due to the unknown pathogenesis of SPNs, the present study was unable to detect changes in Beclin 1 and Bcl-2 expression in comparison with those in normal pancreatic tissues. Finally, due to the short follow-up time, none of the patients with SPN exhibited tumor relapse and all patients were alive by the date of last follow-up. Future studies with a larger sample size are necessary to overcome these limitations.

To conclude, the results of the present study suggest that Beclin 1 upregulation and Bcl-2 downregulation in PDAC promotes cancer progression, and that their expression is inversely correlated. High expression of Bcl-2 is a favorable prognostic indicator in PDAC. Unlike the expression pattern in PDAC, Beclin 1 and Bcl-2 are positively correlated in SPN. High Beclin 1 expression may lead to poor progression of neoplasms.

The authors would like to thank the Science and Technology Department of Liaoning Province for supporting the present study (grant no. 2013225021).

![Immunohistochemical staining for high Beclin 1 expression in PDAC tissues at (A) magnification, ×200 and (D) ×400, in SPN tissues at (B) magnification, ×200 and (E) ×400, and in normal ductal epithelium in CP tissues at (C) magnification, ×200 and (F) ×400. Low Beclin 1 expression in PDAC tissues at (G) magnification, ×200 and (J) ×400, in SPN tissues at (H) magnification, ×200 and (K) ×400, and in normal ductal epithelium in CP tissues at (I) magnification, ×200 and (L) ×400. Pancreatic islet cells were positively stained with Beclin 1 in each sample (arrow). PDAC, pancreatic ductal adenocarcinoma; SPN, solid-pseudopapillary neoplasm; CP, chronic pancreatitis.](ol-14-06-7849-g00){#f1-ol-0-0-7218}

![Immunohistochemical staining for high Bcl-2 expression in PDAC tissues at (A) magnification, ×200 and (D) ×400 in SPN tissues at (B) magnification, ×200 and (E) ×400 and in normal ductal epithelium in CP tissues at (C) magnification, ×200 and (F) ×400. Low Bcl-2 expression in PDAC tissues at (G) magnification, ×200 and (J) ×400 in SPN tissues at (H) magnification, ×200 and (K) ×400 and in normal ductal epithelium in CP tissues at (I) magnification, ×200 and (L) ×400. Lymphocytes in the pancreatic stroma were used as the positive controls (arrow). PDAC, pancreatic ductal adenocarcinoma; SPN, solid-pseudopapillary neoplasm; CP, chronic pancreatitis; Bcl-2, B-cell lymphoma-2.](ol-14-06-7849-g01){#f2-ol-0-0-7218}

![(A and B) Disease-free survival and (C and D) overall survival were analyzed by Kaplan-Meier analysis according to Beclin 1 and Bcl-2 expression status. Bcl-2, B-cell lymphoma-2.](ol-14-06-7849-g02){#f3-ol-0-0-7218}

###### 

Expression of Beclin 1 and Bcl-2 in PDAC and CP tissues.

                Beclin 1                Bcl-2                                                                         
  ------ ------ ----------- ----------- ---------------------------------------------------- ------------ ----------- ------------------------------------------------------
  PDAC   117    43 (36.8)   74 (63.2)   0.047^[a](#tfn1-ol-0-0-7218){ref-type="table-fn"}^   79 (67.5)    38 (32.5)   \<0.001^[a](#tfn1-ol-0-0-7218){ref-type="table-fn"}^
  CP       32   18 (56.3)   14 (43.8)                                                          8 (25.0)   24 (75.0)   

PDAC vs. CP, significantly differently by the χ^2^ test. Bcl-2, B-cell lymphoma-2; PDAC, pancreatic ductal adenocarcinoma; CP, chronic pancreatitis.

###### 

Association of Beclin 1 and Bcl-2 expression with clinicopathological characteristics in pancreatic ductal adenocarcinoma.

                                                                     Beclin 1                Bcl-2                                                                        
  ----------------------------------------------------------- ------ ----------- ----------- ---------------------------------------------------- ----------- ----------- ----------------------------------------------------
  Age, years (mean=58.98)                                                                    0.518                                                                        0.646
    \<58.98                                                     59   20 (33.9)   39 (66.1)                                                        41 (69.5)   18 (30.5)   
    ≥58.98                                                      58   23 (39.7)   35 (60.3)                                                        38 (65.5)   20 (34.5)   
  Sex                                                                                        0.064                                                                        0.485
    Female                                                      47   22 (46.8)   25 (53.2)                                                        30 (63.8)   17 (36.2)   
    Male                                                        70   21 (30.0)   49 (70.0)                                                        49 (70.0)   21 (30.0)   
  Smoker                                                                                     0.170                                                                        0.332
    No                                                          75   31 (41.3)   44 (58.7)                                                        53 (70.7)   22 (29.3)   
    Yes                                                         42   12 (28.6)   30 (71.4)                                                        26 (61.9)   16 (38.1)   
  Diabetes                                                                                   0.631                                                                        0.629
    No                                                        104    39 (37.5)   65 (62.5)                                                        71 (68.3)   33 (31.7)   
    Yes                                                         13   4 (30.8)    9 (69.2)                                                         8 (61.5)    5 (38.5)    
  CA19-9, U/ml^[b](#tfn3-ol-0-0-7218){ref-type="table-fn"}^                                  0.585                                                                        0.871
    ≤37                                                         27   9 (33.3)    18 (66.7)                                                        18 (66.7)   9 (33.3)    
    \>37                                                        79   31 (39.2)   48 (60.8)                                                        54 (68.4)   25 (31.6)   
  CEA, ng/ml^[b](#tfn3-ol-0-0-7218){ref-type="table-fn"}^                                    0.915                                                                        0.996
    ≤5                                                          78   29 (37.2)   49 (62.8)                                                        53 (67.9)   25 (32.1)   
    \>5                                                         25   9 (36.0)    16 (64.0)                                                                                
  Location                                                                                   0.235                                                                        0.017^[a](#tfn2-ol-0-0-7218){ref-type="table-fn"}^
    Head                                                        85   34 (40.0)   51 (60.0)                                                        52 (61.2)   33 (38.8)   
    Body/Tail                                                   32   9 (28.1)    23 (71.9)                                                        27 (84.4)   5 (15.6)    
  Differentiation                                                                            0.001^[a](#tfn2-ol-0-0-7218){ref-type="table-fn"}^                           0.002^[a](#tfn2-ol-0-0-7218){ref-type="table-fn"}^
    Well                                                        21   12 (57.1)   9 (42.9)                                                         11 (52.4)   10 (47.6)   
    Moderate                                                    71   29 (40.8)   42 (59.2)                                                        44 (62.0)   27 (38.0)   
    Poor                                                        25   2 (8.0)     23 (92.0)                                                        24 (96.0)   1 (4.0)     
  T stage                                                                                    0.786                                                                        0.577
    T1/T2                                                       39   15 (38.5)   24 (61.5)                                                        25 (64.1)   14 (35.9)   
    T3/T4                                                       78   28 (35.9)   50 (64.1)                                                        54 (69.2)   24 (30.8)   
  N stage                                                                                    0.390                                                                        0.351
    N0                                                          73   29 (39.7)   44 (60.3)                                                        47 (64.4)   26 (35.6)   
    N1                                                          44   14 (31.8)   30 (68.2)                                                        32 (72.7)   12 (27.3)   
  M stage                                                                                    0.021^[a](#tfn2-ol-0-0-7218){ref-type="table-fn"}^                           0.049^[a](#tfn2-ol-0-0-7218){ref-type="table-fn"}^
    M0                                                        100    41 (41.0)   59 (59.0)                                                        64 (64.0)   36 (36.0)   
    M1                                                          17   2 (11.8)    15 (88.2)                                                        15 (88.2)   2 (11.8)    
  TNM stage                                                                                  0.235                                                                        0.017^[a](#tfn2-ol-0-0-7218){ref-type="table-fn"}^
    I/II                                                        85   34 (40.0)   51 (60.0)                                                        52 (61.2)   33 (38.8)   
    III/IV                                                      32   9 (28.1)    23 (71.9)                                                        27 (84.4)   5 (15.6)    

Significantly differently by the χ^2^ test

preoperative serum CA19-9 was not measured in 11 patients and CEA in 14 patients. Bcl-2, B-cell lymphoma-2; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; TNM, Tumor-Node-Metastasis.

###### 

Association of Beclin 1 and Bcl-2 expression with clinicopathological characteristics in solid-pseudopapillary neoplasms.

                                     Beclin 1                Bcl-2                                                                       
  ---------------------------- ----- ----------- ----------- ---------------------------------------------------- ----------- ---------- -------
  Age, years (mean=32.77)                                    0.207                                                                       0.399
    \<32.77                    28    13 (46.4)   15 (53.6)                                                        22 (78.6)   6 (21.4)   
    ≥32.77                     15    4 (26.7)    11 (73.3)                                                        10 (66.7)   5 (33.3)   
  Sex                                                        0.633                                                                       0.096
    Male                         5   1 (20.0)    4 (80.0)                                                         2 (40.0)    3 (60.0)   
    Female                     38    16 (42.1)   22 (57.9)                                                        30 (78.9)   8 (21.1)   
  Location                                                   0.018^[a](#tfn4-ol-0-0-7218){ref-type="table-fn"}^                          0.116
    Head                       16    10 (62.5)   6 (37.5)                                                         14 (87.5)   2 (12.5)   
    Body/Tail                  27    7 (25.9)    20 (74.1)                                                        18 (66.7)   9 (33.3)   
  Size, cm                                                   0.859                                                                       0.802
    \<6.75                     26    10 (38.5)   16 (61.5)                                                        19 (73.1)   7 (26.9)   
    ≥6.75                      17    7 (41.2)    10 (58.8)                                                        13 (76.5)   4 (23.5)   
  Tumor feature                                              0.834                                                                       0.422
    Solid                      16    6 (37.5)    10 (62.5)                                                        13 (81.3)   3 (18.8)   
    Cystic and solid           27    11 (40.7)   16 (59.3)                                                        19 (70.4)   8 (29.6)   
  Nuclear pleomorphism, HPFs                                 0.031^[a](#tfn4-ol-0-0-7218){ref-type="table-fn"}^                          0.273
    \<10                       36    17 (47.2)   19 (52.8)                                                        28 (77.8)   8 (22.2)   
    ≥10                          7   0 (0.0)     7 (100.0)                                                        4 (57.1)    3 (42.9)   
  Peripancreatic invasion                                    0.446                                                                       0.967
    Yes                          8   2 (25.0)    6 (75.0)                                                         6 (75.0)    2 (25.0)   
    No                         35    15 (42.9)   20 (57.1)                                                        26 (74.3)   9 (25.7)   
  Cytokeratin                                                0.749                                                                       1.000
    +                          21    8 (38.1)    13 (61.9)                                                        15 (71.4)   6 (28.6)   
    −                          16    7           9                                                                11 (68.8)   5 (31.3)   
  Synaptophysin                                              1.000                                                                       1.000
    +                          18    7 (38.9)    11 (61.1)                                                        12 (66.7)   6 (33.3)   
    −                          13    5 (38.5)    8 (61.5)                                                         8 (61.5)    5 (38.5)   

Significantly different by the χ^2^ test. Bcl-2, B-cell lymphoma-2; HPF, high-power field.

###### 

Association between Beclin 1 and Bcl-2 expression.

                      Bcl-2 expression                        
  ------------------- ------------------ ----------- -------- ------------------------------------------------------
  PDAC                                               −0.342   \<0.001^[a](#tfn5-ol-0-0-7218){ref-type="table-fn"}^
    Low expression    20 (17.1)          23 (19.7)            
    High expression   59 (50.4)          15 (12.8)            
  SPN                                                0.365    0.016^[a](#tfn5-ol-0-0-7218){ref-type="table-fn"}^
    Low expression    16 (37.2)          1 (2.3)              
    High expression   16 (37.2)          10 (23.3)            
  CP                                                 0.073    0.692
    Low expression    5 (15.6)           13 (40.6)            
    High expression   3 (9.4)            11 (34.4)            

Significantly different by the χ^2^ test. Bcl-2, B-cell lymphoma-2; PDAC, pancreatic ductal adenocarcinoma; SPN, solid-pseudopapillary neoplasm; CP, chronic pancreatitis.

###### 

Univariate analysis and multivariate analysis of DFS and OS in pancreatic ductal adenocarcinoma.

                            DFS                                                           OS                                                                                                                                                                      
  ------------------- ----- ------ ------------------------------------------------------ ---------------------- ---------------------------------------------------- ------ ------ ------------------------------------------------------ ---------------------- ------------------------------------------------------
  Age, years                       0.856                                                  0.926 (0.558--1.534)   0.764                                                              0.567                                                  1.071 (0.679--1.687)   0.769
    \<58.98           46    6.0                                                                                                                                         59   9.9                                                                                  
    ≥58.98            51    6.5                                                                                                                                         58   11.1                                                                                 
  Sex                              0.292                                                  0.913 (0.509--1.637)   0.760                                                              0.639                                                  1.469 (0.871--2.478)   0.149
    Female            37    7.5                                                                                                                                         47   12.1                                                                                 
    Male              60    5.9                                                                                                                                         70   10.0                                                                                 
  Smoker                           0.786                                                  0.843 (0.482--1.475)   0.550                                                              0.451                                                  0.546 (0.326--0.914)   0.021^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^
    No                61    6.9                                                                                                                                         75   11.6                                                                                 
    Yes               36    5.9                                                                                                                                         42   8.7                                                                                  
  Diabetes                         0.421                                                  1.722 (0.735--4.034)   0.211                                                              0.499                                                  1.336 (0.638--2.798)   0.443
    No                87    6                                                                                                                                         104    10.4                                                                                 
    Yes               10      6                                                                                                                                         13   10.0                                                                                 
  Location                         0.001^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^     0.576 (0.319--1.040)   0.067                                                              0.004^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^     0.826 (0.495--1.379)   0.465
    Head              74    7.5                                                                                                                                         85   12.1                                                                                 
    Body/Tail         23    4.5                                                                                                                                         32   7.2                                                                                  
  Differentiation                  \<0.001^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^   0.399 (0.190--0.839)   0.015^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^                 \<0.001^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^   0.394 (0.201--0.774)   0.007^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^
    Well/Moderate     86    7.0                                                                                                                                         92   12.9                                                                                 
    Poor              11    4.5                                                                                                                                         25   5.9                                                                                  
  T stage                          0.003^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^     0.500 (0.287--0.871)   0.014^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^                 \<0.001^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^   0.307 (0.175--0.539)   \<0.001^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^
    T1/T2             38    12.0                                                                                                                                        39   20.8                                                                                 
    T3/T4             59    6.0                                                                                                                                         78   8.7                                                                                  
  N stage                          0.388                                                  1.084 (0.628--1.870)   0.773                                                              0.022^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^     1.154 (0.679--1.960)   0.596
    N0                71    6.9                                                                                                                                         73   12.8                                                                                 
    N1                26    5.0                                                                                                                                         44   7.9                                                                                  
  M stage                          --                                                     --                     --                                                                 \<0.001^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^   0.380 (0.156--0.923)   0.033^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^
    M0                97    6.0                                                                                                                                       100    12.1                                                                                 
    M1                  0   --                                                                                                                                          17   4.3                                                                                  
  TNM stage                        0.140                                                  0.777 (0.349--1.731)   0.537                                                              \<0.001^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^   1.377 (0.647--2.930)   0.406
    I/II              85    6.5                                                                                                                                         85   12.9                                                                                 
    III/IV            12    3.6                                                                                                                                         32   6.2                                                                                  
  Chemotherapy                     0.871                                                  0.949 (0.515--1.748)   0.866                                                              0.235                                                  2.415 (1.283--4.544)   0.006^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^
    No                80    6.0                                                                                                                                         98   9.3                                                                                  
    Yes               17    7.0                                                                                                                                         19   13.1                                                                                 
  Beclin 1                         0.238                                                  0.870 (0.532--1.423)   0.580                                                              0.038^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^     0.927 (0.557--1.543)   0.771
    Low expression    41    10.0                                                                                                                                        43   14.1                                                                                 
    High expression   56    6.0                                                                                                                                         74   9.1                                                                                  
  Bcl-2                            0.030^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^     1.400 (0.810--2.421)   0.228                                                              0.017^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^     1.850 (1.053--3.249)   0.032^[a](#tfn6-ol-0-0-7218){ref-type="table-fn"}^
    Low expression    61    6.0                                                                                                                                         79   9.1                                                                                  
    High expression   36    10.8                                                                                                                                        38   16.5                                                                                 

Significantly different by the Log-rank test. DFS, disease-free survival; OS, overall survival; TNM, Tumor-Node-Metastasis; Bcl-2, B-cell lymphoma 2.
